Organovo's FXR314 Demonstrates Positive Phase 2 Results in MASH Treatment
Key Insights
Organovo's FXR314 showed a statistically significant reduction in liver fat content compared to placebo in patients with Metabolic Dysfunction-Associated Steatohepatitis (search) (MASH (search)).
The Phase 2 trial demonstrated that 29.2% and 32.2% of patients receiving 3 mg and 6 mg doses of FXR314, respectively, experienced over a 30% reduction in liver fat fraction.
FXR314 was well-tolerated, with a safety profile indicating lower pruritus rates and no significant increases in LDL-C levels, supporting further evaluation for MASH (search) treatment.
Organovo Holdings, Inc. (NASDAQ: ONVO) has announced positive results from its Phase 2 study of FXR314 in patients with Metabolic Dysfunction-Associated Steatohepatitis (search) (MASH (search)). The findings, presented at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD), highlight the drug's potential in reducing liver fat content and maintaining a favorable safety profile.
The randomized, placebo-controlled, multi-centered trial involved 214 patients who received either 3 mg or 6 mg doses of FXR314, or a placebo, over a 16-week period. According to Dr. Eric Lawitz from the Texas Liver Institute and the University of Texas Health San Antonio, the study demonstrated a statistically significant reduction in liver fat content in the FXR314 groups compared to the placebo group. Patients receiving FXR314 experienced a least-squares (LS) mean percent reduction in liver fat at the end of treatment of 22.8% for the 3 mg dose and 17.5% for the 6 mg dose, compared to 6.1% for the placebo.
Key Findings on Liver Fat Reduction
Further analysis revealed that 29.2% and 32.2% of patients in the 3 mg and 6 mg dosage groups, respectively, achieved over a 30% reduction in fat fraction, as measured by MRI. This significant reduction underscores the potential of FXR314 as a therapeutic agent for MASH (search).
Safety and Tolerability
FXR314 was found to be safe and well-tolerated, with most treatment-emergent adverse events being mild to moderate. Notably, the safety profile of FXR314 indicated significantly lower pruritus rates, a common side effect associated with FXR (search) agonists. Additionally, the study reported no significant increases in LDL-C levels, further supporting the drug's favorable safety profile.
Expert Commentary
Dr. Lawitz expressed optimism regarding the drug's potential, emphasizing its liver fat reduction capabilities and safety profile. He stated that the study's findings support further evaluation of FXR314 for treating MASH (search) due to its unique profile and specificity.
Organovo's Technology and Future Applications
Organovo utilizes proprietary technology to develop drugs tested in three-dimensional human tissues that mimic human tissue composition and function. FXR314, the company's lead molecule, is also being considered for application in metabolic liver disease and oncology, expanding its potential therapeutic scope.
Financial Context
Despite the promising Phase 2 results, Organovo's financial health presents a complex picture. The company's market capitalization stands at $5.24 million. While Organovo holds more cash than debt, it is also quickly burning through cash. Revenue for the last twelve months was $0.1 million, with a revenue growth rate of -72.01%.